查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014532

不孕症檢測市場：依產品、類型、技術和最終用戶分類－2026-2032年全球市場預測

Fertility Testing Market by Product, Type, Technology, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，不孕症檢測市場價值將達到 4.176 億美元，到 2026 年將成長至 4.593 億美元，到 2032 年將達到 7.8028 億美元，複合年成長率為 9.34%。

主要市場統計數據
基準年 2025 4.176億美元
預計年份：2026年 4.593億美元
預測年份 2032 7.8028億美元
複合年成長率 (%) 9.34%

策略性介紹揭示了影響不孕症檢測的臨床需求、消費者主導的診斷、技術融合和商業化重點。

目前不孕症檢測領域是一個複雜的生態系統，臨床需求、消費者賦權和技術快速發展相互交織，需要明確的方向和策略遠見。臨床醫生和診斷實驗室正在探索新的患者診療路徑，而個人也越來越容易獲得先進的家庭診斷服務。同時，產品開發商正在將檢查室層級的分析技術與以使用者為中心的數位體驗相結合，以重新定義不孕症的評估、追蹤和治療方式。

技術融合、患者主導的數位化應用以及不斷發展的法規結構如何重新定義生育力檢測生態系統。

不孕症檢測領域正經歷一場變革，這主要得益於消費者健康技術與臨床診斷技術的融合。數位化檢測套組和可重複使用的監測方案提高了對患者進行長期追蹤的能力，而酵素免疫分析法(ELISA) 和數位成像等檢查室分析方法仍然是評估複雜激素和基因的基礎。這些技術的互補性使得混合式醫療模式成為可能，在這種模式下，診所檢測、外部實驗室分析和家庭監測可以並存，從而提供更豐富的臨床見解。

評估不孕症診斷領域累積關稅變化對供應鏈韌性、籌資策略、臨床實務機會和產品設計的影響。

影響診斷組件和成品設備的關稅變化可能會改變生育力檢測相關人員的供應鏈經濟、籌資策略和產品上市時間。進口試劑、感測器和某些電子元件關稅的增加，可能會導致診所平台和家用檢測套組的單位成本上升，迫使製造商和經銷商重新評估籌資策略和合約條款。為此，累積公司正在探索將組裝流程組裝、選擇替代供應商以及重新設計材料清單(BOM)，以降低關稅敏感組件的比例。

進行詳細的細分分析，以確定每種測試類型、產品管道、檢測技術的不同需求因素以及最終用戶採用趨勢。

市場區隔揭示了每種檢測形式、產品管道、技術和最終用戶的不同需求促進因素和營運考慮。按類型分類，檢測途徑包括用於監測內分泌狀態的激素檢測、用於識別排卵期的排卵檢測、用於確認懷孕的懷孕檢測以及用於評估男性生育能力的精子品質檢測。每種檢測的分析複雜性和臨床解讀各不相同，對產品或服務的要求也各有差異。

區域趨勢和市場准入要求決定了全球主要地區的臨床引入、報銷和分銷策略。

區域趨勢影響著整個生育力檢測領域的臨床路徑、監管預期和商業重點。在美洲，市場特徵是私部門創新能力強、消費者直接參與度高、與保險公司的諮詢關係成熟，以及專注於將家庭檢測與遠端醫療和診所追蹤相結合的綜合數位解決方案。這些因素為基於訂閱的監測服務以及診斷開發公司與醫療保健網路之間的夥伴關係創造了有利條件。

透過臨床檢驗、數位化整合、策略夥伴關係和適應性製造方法實現競爭差異化。

在生育力檢測領域，主要企業透過多種方式脫穎而出，包括平台覆蓋範圍、臨床檢驗深度、數位整合以及通路夥伴關係。有些公司大力投資，拓展檢查室能力和參考服務，以支援複雜的基因和荷爾蒙檢測；而有些公司則專注於以消費者為中心的設計，致力於開發具備無縫應用程式解讀功能的家用檢測套組。縱觀整個競爭格局，成功的公司能夠在嚴謹的分析性能、清晰的臨床效用以及能夠減輕患者和醫療服務提供者負擔的用戶體驗之間取得平衡。

領導者面臨的實際挑戰包括：加強證據、實現模組化產品設計、確保供應彈性以及將診斷整合到護理路徑中。

業界領導者應優先考慮一系列切實可行的舉措，以增強韌性、加快部署並保障臨床完整性。首先，投資雙路徑臨床證據，以證明產品在從照護現場到參考實驗室等所有情境下的分析有效性和實際效用。此類證據有助於與保險公司對話並增強臨床醫生的信心。其次，設計採用模組化硬體和軟體組件的產品系列，以實現產品的快速重新配置，同時最大限度地降低關稅和零件短缺的風險。

採用嚴謹的多方法研究方法，結合關鍵相關人員的訪談、臨床和監管二手文獻的整合以及透明的資料三角驗證。

本執行摘要的研究基於多方面方法，整合了質性訪談、二手文獻和專家交叉驗證。關鍵數據來源包括對臨床醫生、診斷實驗室經理、採購經理和數位醫療行業高管的結構化訪談，以了解他們對應用障礙、工作流程整合和未滿足的臨床需求等方面的實際觀點。二手分析整合了監管指南、產品技術規格和同行評審文獻，以確保分析結論是基於檢驗的技術和臨床標準。

強調需要以證據為基礎的創新、互操作系統和營運彈性，並整合策略重點以加速臨床部署。

不孕症檢測領域正處於一個轉折點，技術成熟、患者期望不斷變化以及經營模式不斷演進交織在一起，為相關人員創造了新的機會和責任。診斷開發人員和服務供應商必須適應日益混合化的醫療環境，在這種環境中，家庭監測與檢查室檢測相輔相成，數據整合成為臨床決策的基礎。因此，檢測流程、結果解讀以及基於結果的應對措施都在變化，這需要產品開發、臨床檢驗和銷售管道之間採取協調一致的方法。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：不孕症檢測市場：依產品分類

  • 診所檢查
    • 荷爾蒙水平檢測
    • 診所排卵測試
    • 診所內妊娠測試
  • 基因檢測
    • 攜帶者篩檢
    • 懷孕前基因檢測
  • 家用檢測套組
    • 數位檢測套組
    • 可重複使用的監測套件
    • 試紙條式檢測套組
  • 檢查服務
    • 即時檢測服務
    • 外部測試實驗室服務

第9章：不孕症檢測市場：按類型分類

  • 荷爾蒙測試
  • 排卵測試
  • 妊娠測試
  • 精子品質檢測

第10章：不孕症檢測市場：依技術分類

  • 月球成像
  • 酵素免疫分析法
  • 側向流動免疫檢測

第11章：不孕症檢測市場：依最終用戶分類

  • 診斷檢測實驗室
  • 不孕症治療診所
  • 醫院
  • 個人

第12章：不孕症檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：不孕症檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：不孕症檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國不孕症檢測市場

第16章：中國不孕症檢測市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AccuMed
  • AccuQuik
  • bioZhena Corporation
  • Church & Dwight Co., Inc.
  • Clinical Guard
  • Daysy Fertility Monitor
  • Fairhaven Health
  • Femometer
  • Geratherm Medical AG
  • Get Stix, Inc.
  • Kegg by Lady Technologies, Inc.
  • Mira Care
  • Piramal Health
  • Proov
  • Samplytics Technologies Private Limited
  • Swiss Precision Diagnostics GmbH
  • TaiDoc Technology Corporation
  • Tempdrop
  • The Boots Company PLC
  • UEBE Medical GmbH
  • Valley Electronics AG
  • viO HealthTech Limited
  • Wondfo Biotech
Product Code: MRR-4348D129FB2F

The Fertility Testing Market was valued at USD 417.60 million in 2025 and is projected to grow to USD 459.30 million in 2026, with a CAGR of 9.34%, reaching USD 780.28 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 417.60 million
Estimated Year [2026] USD 459.30 million
Forecast Year [2032] USD 780.28 million
CAGR (%) 9.34%

A strategic primer illuminating clinical demand, consumer-driven diagnostics, technological convergence, and commercialization priorities shaping fertility testing

The fertility testing landscape sits at the intersection of clinical demand, consumer empowerment, and rapid technology advancement, creating a complex ecosystem that requires clarity and strategic foresight. Clinical practitioners and diagnostic laboratories are navigating new patient pathways while individuals are accessing increasingly sophisticated home diagnostics. Concurrently, product innovators are converging laboratory-grade analytics with user-centric digital experiences, reshaping how fertility health is assessed, tracked, and acted upon.

This executive summary synthesizes core trends and practical implications for stakeholders across the value chain. It emphasizes the evolving role of point-of-care modalities, the maturation of genetic screening services in preconception care, and the expanding influence of digital diagnostics that translate biological signals into actionable guidance. Moreover, the narrative highlights how regulatory shifts, reimbursement conversations, and payer scrutiny are influencing clinical adoption and commercial strategies.

By framing the current environment through clinical pathways, technology enablers, and end-user expectations, the overview provides a foundation for informed decision-making. Leaders will find context that supports prioritization of investments, identifies operational vulnerabilities, and surfaces partnership opportunities that accelerate access to high-value patient segments while maintaining clinical rigor and quality assurance.

How technological convergence, patient-driven digital adoption, and evolving regulatory frameworks are redefining the fertility testing ecosystem

The landscape of fertility testing is undergoing transformative shifts driven by convergence between consumer health technology and clinical diagnostics. Digital test kits and reusable monitor solutions are enhancing longitudinal tracking capabilities, while laboratory-based assays such as enzyme linked immunosorbent assays and digital imaging continue to provide the analytical backbone for complex hormone and genetic evaluations. This technological complementarity is enabling hybrid care models where in-clinic testing, reference laboratory analytics, and at-home monitoring coexist to deliver richer clinical narratives.

Simultaneously, patient behavior is evolving; individuals are seeking earlier, more frequent, and more personalized insights into reproductive health, prompting growth in both direct-to-consumer offerings and clinician-mediated home testing programs. This demand is reinforcing investments in user experience, telehealth integration, and data interoperability so that test results can feed care pathways and support shared decision-making. Regulatory bodies are responding with updated guidance that balances accessibility with the need for analytical validity and appropriate clinical interpretation, which in turn is shaping product design and commercialization timelines.

Finally, commercial models are shifting as providers and suppliers explore bundled services, subscription monitoring, and outcome-driven pricing to align incentives across stakeholders. These dynamics collectively point toward a future where fertility testing is more continuous, digitally enabled, and integrated into broader reproductive health journeys.

Assessment of how cumulative tariff shifts influence supply chain resilience, procurement strategy, clinical access, and product design across fertility diagnostics

Tariff changes affecting diagnostics components and finished devices can alter supply chain economics, procurement strategies, and time-to-market dynamics for fertility testing stakeholders. Cumulatively, increased duties on imported reagents, sensors, and certain electronic components have the potential to raise unit costs for both clinic-based platforms and home test kits, prompting manufacturers and distributors to reassess sourcing strategies and contract terms. In response, many companies consider nearshoring assembly, qualifying alternate suppliers, and redesigning product bills of materials to reduce tariff-sensitive content.

Operationally, tariffs can extend lead times as customs clearance and compliance checks become more complex, which may disrupt inventory planning for point-of-care testing services and reference labs. These delays incentivize higher safety stocks for critical reagents and consumables, thereby increasing working capital requirements. From a clinical access perspective, cost pressures could influence pricing and reimbursement negotiations with payers and hospital systems, and could also slow the adoption cadence for newer, higher-cost diagnostic modalities until value propositions are clearly demonstrated.

Strategically, tariffs accelerate supplier consolidation conversations and increase the importance of contractual agility. Procurement teams are placing greater emphasis on total landed cost analysis, tariff mitigation clauses, and multi-sourcing arrangements to maintain service levels. At the same time, companies with modular designs and software-driven differentiation may be better positioned to absorb discrete cost shocks without compromising the quality of clinical reporting or patient experience.

Deep segmentation analysis revealing distinct demand drivers across test types, product channels, assay technologies, and end-user adoption profiles

Segmentation reveals distinct demand drivers and operational considerations across testing formats, product channels, technologies, and end users. Based on type, testing pathways encompass hormone tests that monitor endocrine status, ovulation tests that pinpoint fertile windows, pregnancy tests that confirm conception, and sperm quality tests that evaluate male fertility parameters. These type-specific assays differ in analytical complexity and clinical interpretation, leading to divergent product and service requirements.

Based on product, the market spans clinic-based tests, genetic tests, home test kits, and lab services. Clinic-based tests include hormone panel assays, in-clinic ovulation diagnostics, and in-clinic pregnancy confirmation services that rely on trained personnel and integrated clinical workflows. Genetic tests cover carrier screening and preconception genetic assessments that demand high analytical accuracy and robust counseling frameworks. Home test kits range from digital test kits with app connectivity to reusable monitor kits and cost-effective strip-based options that prioritize ease of use. Lab services incorporate point-of-care testing services for near-patient diagnostics alongside reference lab services that support high-complexity assays and advanced analytics.

Based on technology, platforms are differentiated by digital imaging techniques, enzyme linked immunosorbent assay methodologies for quantitative biomarker detection, and lateral flow immunoassay approaches that enable rapid, qualitative results. Based on end user, the ecosystem serves diagnostic laboratories, fertility clinics, hospitals, and individual consumers, each with unique quality, regulatory, and data integration expectations. Recognizing these segmentation layers helps stakeholders prioritize product development, distribution models, and clinical engagement strategies tailored to the specific demands of each cohort.

Regional dynamics and market-entry imperatives that determine clinical adoption, reimbursement, and distribution strategies across major global territories

Regional dynamics shape clinical pathways, regulatory expectations, and commercial priorities across the fertility testing landscape. In the Americas, markets are characterized by a high degree of private-sector innovation, strong direct-to-consumer engagement, mature payer discussions, and an emphasis on integrated digital solutions that link home testing with telehealth and clinic follow-up. These factors create fertile ground for subscription-based monitoring services and partnerships between diagnostic developers and care networks.

Across Europe, the Middle East & Africa, regulatory harmonization, public healthcare procurement frameworks, and diverse access models influence how fertility tests are adopted. In many markets, reimbursement mechanisms and centralized procurement shape supplier selection, while countries with advanced genetics infrastructures are accelerating the integration of carrier and preconception screening into routine care. In contrast, regions with constrained laboratory capacity are prioritizing robust point-of-care solutions and simpler, high-value diagnostic tools that reduce referral burdens.

In the Asia-Pacific region, rapid digital adoption, sizable consumer markets, and expanding private healthcare sectors are driving growth in home testing and hybrid care models. Local manufacturing initiatives and regional supply-chain investments are also influencing product availability and cost structures. Collectively, these regional nuances highlight the need for market-entry strategies that balance regulatory compliance, distribution partnerships, and culturally appropriate patient engagement to maximize uptake and clinical impact.

Competitive differentiation through clinical validation, digital integration, strategic partnerships, and adaptive manufacturing approaches

Leading companies operating in fertility testing are differentiating along multiple dimensions: platform breadth, depth of clinical validation, digital integration, and channel partnerships. Some firms invest heavily in expanding laboratory capabilities and reference services to support complex genetic and hormone assays, while others focus on consumer-centric design to scale home test kits with seamless app-based interpretation. Across the competitive set, successful players balance rigorous analytical performance with clear clinical utility and user experience that reduces friction for both patients and providers.

Strategic collaborations between diagnostics developers, fertility clinics, and digital health platforms are becoming more common as companies seek to embed testing within longitudinal care pathways. Partnerships that enable bundled service offerings-combining initial screening, confirmatory laboratory testing, and clinician-led follow-up-are proving effective at driving adherence and generating richer outcome data. Additionally, M&A and licensing activity is reshaping capability stacks, with acquisitions frequently aimed at adding assay expertise, digital engagement tools, or regulatory footholds in target markets.

Companies prioritizing open data architectures and interoperability are positioning themselves to win in an environment where integrated care and outcome measurement matter. Finally, those with modular product roadmaps and flexible manufacturing strategies can react more nimbly to tariff pressures, supply chain disruptions, and changing reimbursement landscapes, thereby maintaining continuity of supply and preserving clinician and patient trust.

Practical imperatives for leaders to strengthen evidence, enable modular product design, secure supply resilience, and integrate diagnostics into care pathways

Industry leaders should prioritize a set of pragmatic actions that enhance resilience, accelerate adoption, and protect clinical integrity. First, invest in dual-pathway clinical evidence that demonstrates both analytical validity and real-world clinical utility across settings ranging from point of care to reference labs; such evidence supports payer conversations and clinician confidence. Next, design product portfolios with modular hardware and software components to enable rapid product reconfiguration and minimize exposure to tariff and component shortages.

Simultaneously, deepen partnerships with fertility clinics, diagnostic laboratories, and telehealth providers to create end-to-end patient journeys that reduce abandonment and improve diagnostic-to-treatment conversion. Align commercial models with outcomes by piloting bundled services and subscription monitoring to capture lifetime patient value and encourage adherence. Strengthen procurement and supplier management by implementing total landed cost analytics and multi-source strategies to mitigate single-supplier risk and customs-driven delays.

Finally, prioritize data governance, interoperability, and clinician-facing decision support so that test results translate into actionable care plans. By focusing on evidence generation, modular design, strategic partnerships, procurement sophistication, and data integration, industry leaders can convert market complexity into competitive advantage and sustained clinical impact.

Rigorous multi-method research approach combining primary stakeholder interviews, secondary clinical and regulatory synthesis, and transparent data triangulation

The research underpinning this executive summary is built on a multi-method approach that integrates primary qualitative interviews, secondary literature synthesis, and cross-validation with subject-matter experts. Primary inputs included structured interviews with clinicians, diagnostic laboratory directors, procurement leaders, and digital health executives to capture front-line perspectives on adoption barriers, workflow integration, and unmet clinical needs. Secondary analysis synthesized regulatory guidance, product technical specifications, and peer-reviewed literature to ensure analytical assertions were grounded in verifiable technical and clinical standards.

Data triangulation was employed to reconcile differing stakeholder viewpoints and identify robust themes. Where quantitative datasets were incorporated, care was taken to validate sources and ensure appropriate interpretation without projecting forward-looking estimates. The methodology emphasizes transparency of assumptions, clear documentation of data provenance, and a candid assessment of limitations, including potential regional heterogeneity and variability in clinical practice patterns. Ethical considerations and data privacy standards guided engagement protocols for interviews and the handling of any de-identified clinical datasets.

Finally, the research process prioritized actionable insight over descriptive reporting, using iterative synthesis to transform evidence into strategic recommendations that are relevant to commercial, clinical, and policy stakeholders operating in the fertility testing domain.

Synthesis of strategic priorities highlighting the need for evidence-based innovation, interoperable systems, and operational resilience to accelerate clinical adoption

The fertility testing domain is at an inflection point where technological maturation, changing patient expectations, and evolving commercial models converge to create new opportunities and responsibilities for stakeholders. Diagnostics developers and service providers must navigate an increasingly hybrid environment in which home-based monitoring complements laboratory-grade assays, and where data integration underpins clinical decision-making. As a result, the pathways by which tests are delivered, interpreted, and acted upon are changing, requiring coordinated responses across product development, clinical validation, and commercial channels.

Stakeholders who invest in rigorous evidence generation, prioritize interoperability, and structure partnerships with clinical care providers will be best placed to demonstrate value and secure long-term adoption. Equally important is the need for operational resilience in the face of supply chain and tariff pressures, which underscores the importance of procurement sophistication and flexible manufacturing strategies. Ultimately, the field will progress most effectively when innovations are paired with robust clinical governance and patient-centered design, ensuring that diagnostic advancements translate into improved reproductive health outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Fertility Testing Market, by Product

  • 8.1. Clinic Based Tests
    • 8.1.1. Hormone Panel Tests
    • 8.1.2. In-Clinic Ovulation Tests
    • 8.1.3. In-Clinic Pregnancy Tests
  • 8.2. Genetic Tests
    • 8.2.1. Carrier Screening
    • 8.2.2. Preconception Genetic Tests
  • 8.3. Home Test Kits
    • 8.3.1. Digital Test Kits
    • 8.3.2. Reusable Monitor Kits
    • 8.3.3. Strip Based Test Kits
  • 8.4. Lab Services
    • 8.4.1. Point Of Care Testing Services
    • 8.4.2. Reference Lab Services

9. Fertility Testing Market, by Type

  • 9.1. Hormone Test
  • 9.2. Ovulation Test
  • 9.3. Pregnancy Test
  • 9.4. Sperm Quality Test

10. Fertility Testing Market, by Technology

  • 10.1. Digital Imaging
  • 10.2. Enzyme Linked Immunosorbent Assay
  • 10.3. Lateral Flow Immunoassay

11. Fertility Testing Market, by End User

  • 11.1. Diagnostic Laboratories
  • 11.2. Fertility Clinics
  • 11.3. Hospitals
  • 11.4. Individuals

12. Fertility Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Fertility Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Fertility Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Fertility Testing Market

16. China Fertility Testing Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. AccuMed
  • 17.7. AccuQuik
  • 17.8. bioZhena Corporation
  • 17.9. Church & Dwight Co., Inc.
  • 17.10. Clinical Guard
  • 17.11. Daysy Fertility Monitor
  • 17.12. Fairhaven Health
  • 17.13. Femometer
  • 17.14. Geratherm Medical AG
  • 17.15. Get Stix, Inc.
  • 17.16. Kegg by Lady Technologies, Inc.
  • 17.17. Mira Care
  • 17.18. Piramal Health
  • 17.19. Proov
  • 17.20. Samplytics Technologies Private Limited
  • 17.21. Swiss Precision Diagnostics GmbH
  • 17.22. TaiDoc Technology Corporation
  • 17.23. Tempdrop
  • 17.24. The Boots Company PLC
  • 17.25. UEBE Medical GmbH
  • 17.26. Valley Electronics AG
  • 17.27. viO HealthTech Limited
  • 17.28. Wondfo Biotech

LIST OF FIGURES

  • FIGURE 1. GLOBAL FERTILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FERTILITY TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL FERTILITY TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL FERTILITY TESTING MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL FERTILITY TESTING MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FERTILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL FERTILITY TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FERTILITY TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL FERTILITY TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FERTILITY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES FERTILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA FERTILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FERTILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FERTILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FERTILITY TESTING MARKET SIZE, BY CLINIC BASED TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FERTILITY TESTING MARKET SIZE, BY CLINIC BASED TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FERTILITY TESTING MARKET SIZE, BY CLINIC BASED TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FERTILITY TESTING MARKET SIZE, BY CLINIC BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FERTILITY TESTING MARKET SIZE, BY HORMONE PANEL TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FERTILITY TESTING MARKET SIZE, BY HORMONE PANEL TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FERTILITY TESTING MARKET SIZE, BY HORMONE PANEL TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL FERTILITY TESTING MARKET SIZE, BY IN-CLINIC OVULATION TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL FERTILITY TESTING MARKET SIZE, BY IN-CLINIC OVULATION TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FERTILITY TESTING MARKET SIZE, BY IN-CLINIC OVULATION TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FERTILITY TESTING MARKET SIZE, BY IN-CLINIC PREGNANCY TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FERTILITY TESTING MARKET SIZE, BY IN-CLINIC PREGNANCY TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FERTILITY TESTING MARKET SIZE, BY IN-CLINIC PREGNANCY TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FERTILITY TESTING MARKET SIZE, BY GENETIC TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FERTILITY TESTING MARKET SIZE, BY GENETIC TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FERTILITY TESTING MARKET SIZE, BY GENETIC TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FERTILITY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FERTILITY TESTING MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FERTILITY TESTING MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FERTILITY TESTING MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FERTILITY TESTING MARKET SIZE, BY PRECONCEPTION GENETIC TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FERTILITY TESTING MARKET SIZE, BY PRECONCEPTION GENETIC TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FERTILITY TESTING MARKET SIZE, BY PRECONCEPTION GENETIC TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FERTILITY TESTING MARKET SIZE, BY HOME TEST KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FERTILITY TESTING MARKET SIZE, BY HOME TEST KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FERTILITY TESTING MARKET SIZE, BY HOME TEST KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FERTILITY TESTING MARKET SIZE, BY HOME TEST KITS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FERTILITY TESTING MARKET SIZE, BY DIGITAL TEST KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FERTILITY TESTING MARKET SIZE, BY DIGITAL TEST KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FERTILITY TESTING MARKET SIZE, BY DIGITAL TEST KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FERTILITY TESTING MARKET SIZE, BY REUSABLE MONITOR KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FERTILITY TESTING MARKET SIZE, BY REUSABLE MONITOR KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FERTILITY TESTING MARKET SIZE, BY REUSABLE MONITOR KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FERTILITY TESTING MARKET SIZE, BY STRIP BASED TEST KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FERTILITY TESTING MARKET SIZE, BY STRIP BASED TEST KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FERTILITY TESTING MARKET SIZE, BY STRIP BASED TEST KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FERTILITY TESTING MARKET SIZE, BY LAB SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FERTILITY TESTING MARKET SIZE, BY LAB SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FERTILITY TESTING MARKET SIZE, BY LAB SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FERTILITY TESTING MARKET SIZE, BY LAB SERVICES, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FERTILITY TESTING MARKET SIZE, BY POINT OF CARE TESTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FERTILITY TESTING MARKET SIZE, BY POINT OF CARE TESTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FERTILITY TESTING MARKET SIZE, BY POINT OF CARE TESTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FERTILITY TESTING MARKET SIZE, BY REFERENCE LAB SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FERTILITY TESTING MARKET SIZE, BY REFERENCE LAB SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FERTILITY TESTING MARKET SIZE, BY REFERENCE LAB SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FERTILITY TESTING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FERTILITY TESTING MARKET SIZE, BY HORMONE TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FERTILITY TESTING MARKET SIZE, BY HORMONE TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FERTILITY TESTING MARKET SIZE, BY HORMONE TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FERTILITY TESTING MARKET SIZE, BY OVULATION TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FERTILITY TESTING MARKET SIZE, BY OVULATION TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FERTILITY TESTING MARKET SIZE, BY OVULATION TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FERTILITY TESTING MARKET SIZE, BY PREGNANCY TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FERTILITY TESTING MARKET SIZE, BY PREGNANCY TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FERTILITY TESTING MARKET SIZE, BY PREGNANCY TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FERTILITY TESTING MARKET SIZE, BY SPERM QUALITY TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL FERTILITY TESTING MARKET SIZE, BY SPERM QUALITY TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FERTILITY TESTING MARKET SIZE, BY SPERM QUALITY TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FERTILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FERTILITY TESTING MARKET SIZE, BY DIGITAL IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FERTILITY TESTING MARKET SIZE, BY DIGITAL IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL FERTILITY TESTING MARKET SIZE, BY DIGITAL IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL FERTILITY TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL FERTILITY TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL FERTILITY TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL FERTILITY TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL FERTILITY TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL FERTILITY TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL FERTILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL FERTILITY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL FERTILITY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL FERTILITY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL FERTILITY TESTING MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL FERTILITY TESTING MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL FERTILITY TESTING MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL FERTILITY TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL FERTILITY TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL FERTILITY TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL FERTILITY TESTING MARKET SIZE, BY INDIVIDUALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL FERTILITY TESTING MARKET SIZE, BY INDIVIDUALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL FERTILITY TESTING MARKET SIZE, BY INDIVIDUALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL FERTILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS FERTILITY TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS FERTILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS FERTILITY TESTING MARKET SIZE, BY CLINIC BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS FERTILITY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS FERTILITY TESTING MARKET SIZE, BY HOME TEST KITS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS FERTILITY TESTING MARKET SIZE, BY LAB SERVICES, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS FERTILITY TESTING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS FERTILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS FERTILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA FERTILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA FERTILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA FERTILITY TESTING MARKET SIZE, BY CLINIC BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA FERTILITY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA FERTILITY TESTING MARKET SIZE, BY HOME TEST KITS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA FERTILITY TESTING MARKET SIZE, BY LAB SERVICES, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA FERTILITY TESTING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA FERTILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA FERTILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA FERTILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA FERTILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA FERTILITY TESTING MARKET SIZE, BY CLINIC BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA FERTILITY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA FERTILITY TESTING MARKET SIZE, BY HOME TEST KITS, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA FERTILITY TESTING MARKET SIZE, BY LAB SERVICES, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA FERTILITY TESTING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA FERTILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA FERTILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA FERTILITY TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA FERTILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA FERTILITY TESTING MARKET SIZE, BY CLINIC BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA FERTILITY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA FERTILITY TESTING MARKET SIZE, BY HOME TEST KITS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA FERTILITY TESTING MARKET SIZE, BY LAB SERVICES, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA FERTILITY TESTING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA FERTILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA FERTILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE FERTILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE FERTILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE FERTILITY TESTING MARKET SIZE, BY CLINIC BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE FERTILITY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE FERTILITY TESTING MARKET SIZE, BY HOME TEST KITS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE FERTILITY TESTING MARKET SIZE, BY LAB SERVICES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE FERTILITY TESTING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE FERTILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE FERTILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST FERTILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST FERTILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST FERTILITY TESTING MARKET SIZE, BY CLINIC BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST FERTILITY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST FERTILITY TESTING MARKET SIZE, BY HOME TEST KITS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST FERTILITY TESTING MARKET SIZE, BY LAB SERVICES, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST FERTILITY TESTING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST FERTILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST FERTILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA FERTILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA FERTILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA FERTILITY TESTING MARKET SIZE, BY CLINIC BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA FERTILITY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA FERTILITY TESTING MARKET SIZE, BY HOME TEST KITS, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA FERTILITY TESTING MARKET SIZE, BY LAB SERVICES, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA FERTILITY TESTING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA FERTILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA FERTILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC FERTILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC FERTILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC FERTILITY TESTING MARKET SIZE, BY CLINIC BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC FERTILITY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC FERTILITY TESTING MARKET SIZE, BY HOME TEST KITS, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC FERTILITY TESTING MARKET SIZE, BY LAB SERVICES, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC FERTILITY TESTING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC FERTILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC FERTILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL FERTILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN FERTILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN FERTILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN FERTILITY TESTING MARKET SIZE, BY CLINIC BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN FERTILITY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN FERTILITY TESTING MARKET SIZE, BY HOME TEST KITS, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN FERTILITY TESTING MARKET SIZE, BY LAB SERVICES, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN FERTILITY TESTING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN FERTILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN FERTILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. GCC FERTILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GCC FERTILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 170. GCC FERTILITY TESTING MARKET SIZE, BY CLINIC BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 171. GCC FERTILITY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 172. GCC FERTILITY TESTING MARKET SIZE, BY HOME TEST KITS, 2018-2032 (USD MILLION)
  • TABLE 173. GCC FERTILITY TESTING MARKET SIZE, BY LAB SERVICES, 2018-2032 (USD MILLION)
  • TABLE 174. GCC FERTILITY TESTING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC FERTILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. GCC FERTILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION FERTILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION FERTILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION FERTILITY TESTING MARKET SIZE, BY CLINIC BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION FERTILITY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION FERTILITY TESTING MARKET SIZE, BY HOME TEST KITS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION FERTILITY TESTING MARKET SIZE, BY LAB SERVICES, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION FERTILITY TESTING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION FERTILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION FERTILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS FERTILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS FERTILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS FERTILITY TESTING MARKET SIZE, BY CLINIC BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS FERTILITY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS FERTILITY TESTING MARKET SIZE, BY HOME TEST KITS, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS FERTILITY TESTING MARKET SIZE, BY LAB SERVICES, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS FERTILITY TESTING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS FERTILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS FERTILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. G7 FERTILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. G7 FERTILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 197. G7 FERTILITY TESTING MARKET SIZE, BY CLINIC BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 198. G7 FERTILITY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 199. G7 FERTILITY TESTING MARKET SIZE, BY HOME TEST KITS, 2018-2032 (USD MILLION)
  • TABLE 200. G7 FERTILITY TESTING MARKET SIZE, BY LAB SERVICES, 2018-2032 (USD MILLION)
  • TABLE 201. G7 FERTILITY TESTING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. G7 FERTILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. G7 FERTILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. NATO FERTILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. NATO FERTILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 206. NATO FERTILITY TESTING MARKET SIZE, BY CLINIC BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 207. NATO FERTILITY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 208. NATO FERTILITY TESTING MARKET SIZE, BY HOME TEST KITS, 2018-2032 (USD MILLION)
  • TABLE 209. NATO FERTILITY TESTING MARKET SIZE, BY LAB SERVICES, 2018-2032 (USD MILLION)
  • TABLE 210. NATO FERTILITY TESTING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO FERTILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. NATO FERTILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL FERTILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES FERTILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES FERTILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES FERTILITY TESTING MARKET SIZE, BY CLINIC BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES FERTILITY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES FERTILITY TESTING MARKET SIZE, BY HOME TEST KITS, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES FERTILITY TESTING MARKET SIZE, BY LAB SERVICES, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES FERTILITY TESTING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES FERTILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES FERTILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA FERTILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA FERTILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA FERTILITY TESTING MARKET SIZE, BY CLINIC BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA FERTILITY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA FERTILITY TESTING MARKET SIZE, BY HOME TEST KITS, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA FERTILITY TESTING MARKET SIZE, BY LAB SERVICES, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA FERTILITY TESTING MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA FERTILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA FERTILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)